about
Evidence that low doses of Taxol enhance the functional transactivatory properties of p53 on p21 waf promoter in MCF-7 breast cancer cellsPeroxisome proliferator-activated receptor-gamma activates p53 gene promoter binding to the nuclear factor-kappaB sequence in human MCF7 breast cancer cells.Akt2 inhibition enables the forkhead transcription factor FoxO3a to have a repressive role in estrogen receptor alpha transcriptional activity in breast cancer cells.Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element.Role of the IGF-I receptor in the regulation of cell-cell adhesion: implications in cancer development and progression.Bergapten drives autophagy through the up-regulation of PTEN expression in breast cancer cells.Expression of nuclear insulin receptor substrate 1 in breast cancer.Androgens downregulate miR-21 expression in breast cancer cells underlining the protective role of androgen receptorDAX-1, as an androgen-target gene, inhibits aromatase expression: a novel mechanism blocking estrogen-dependent breast cancer cell proliferationInteraction between estrogen receptor alpha and insulin/IGF signaling in breast cancer.The estrogen receptor α is the key regulator of the bifunctional role of FoxO3a transcription factor in breast cancer motility and invasiveness.Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promoters.Estradiol via estrogen receptor beta influences ROS levels through the transcriptional regulation of SIRT3 in human seminoma TCam-2 cells.Mesoporous Silica Nanoparticles in Cancer Therapy: Relevance of the Targeting Function.Androgens inhibit aromatase expression through DAX-1: insights into the molecular link between hormone balance and Leydig cancer development.Chenodeoxycholic acid through a TGR5-dependent CREB signaling activation enhances cyclin D1 expression and promotes human endometrial cancer cell proliferation.PEG-templated mesoporous silica nanoparticles exclusively target cancer cells.Insulin receptor substrate 1 modulates the transcriptional activity and the stability of androgen receptor in breast cancer cells.The estrogen receptor alpha:insulin receptor substrate 1 complex in breast cancer: structure-function relationships.Retinoic acid mediates degradation of IRS-1 by the ubiquitin-proteasome pathway, via a PKC-dependant mechanism.Leptin secretion by human ejaculated spermatozoa.17β-estradiol enhances α(5) integrin subunit gene expression through ERα-Sp1 interaction and reduces cell motility and invasion of ERα-positive breast cancer cells.Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells.Red wine consumption may affect sperm biology: the effects of different concentrations of the phytoestrogen myricetin on human male gamete function.FoxO3a mediates the inhibitory effects of the antiepileptic drug Lamotrigine on breast cancer growth.Controlled release of sunitinib in targeted cancer therapy: smart magnetically responsive hydrogels as restricted access materialsHybrid Mesoporous Silica for Drug TargetingMagnetic molecularly imprinted polymers (MMIPs) for carbazole derivative release in targeted cancer therapyHuman Sperm Anatomy: Different Expression and Localization of Phosphatidylinositol 3-Kinase in Normal and Varicocele Human SpermatozoaPreparation and cell inclusion of fluorescent folic acid-functionalized mesoporous silica microspheres potentially useful for drug targetingIGF-I Receptor-induced Cell-Cell Adhesion of MCF-7 Breast Cancer Cells Requires the Expression of Junction Protein ZO-1Dealing with Skin and Blood-Brain Barriers: The Unconventional Challenges of Mesoporous Silica NanoparticlesFoxO3a as a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast CancerValproic Acid Addresses Neuroendocrine Differentiation of LNCaP Cells and Maintains Cell SurvivalModulating Tumor-Associated Macrophage Polarization by Synthetic and Natural PPARγ Ligands as a Potential Target in Breast Cancer
P50
Q24317614-1707246B-A286-4B13-A42A-AF7911EA5403Q33252788-A8C2BE00-0BF7-4DB6-8926-CEA670E2B5E9Q33614071-A1D72668-A68B-434C-B3E1-836E90B09CB0Q34122589-0C801762-1265-4C86-BC52-478955DFCFD2Q35031402-202CD7BD-31C7-4E66-AF7C-053A4944CC6BQ35838511-76ABDBFF-B24A-432B-AB3E-0EA737E4F62BQ35954427-234CCEA1-4616-4F7E-B323-3D9FDEE0E598Q37022250-B75E7E65-4D79-4A6E-A50E-17B1EF876395Q37062022-2B0B7AE0-4AF8-410D-AD29-E22946EEB219Q37320077-B290E736-BB14-43FE-BF92-FC2582ECC49EQ37492303-689D00EF-43EF-42EE-91C9-6D1346317789Q38337562-1F83CE4B-7817-48AA-AFDD-28054C6AB73FQ38689132-D5C9236F-A923-4280-93F8-9BB7C9A404DDQ38782315-9091F0E5-3344-49D3-9FB4-045154C464B4Q38918424-7D25CB71-7D2B-43F8-B9FE-E4828F677622Q39321742-22F6F368-4CF2-43AC-92E1-2401B942BF0EQ39513662-473087C6-AA65-43E9-B409-E47095029210Q39975924-305893F3-1E78-4FBB-AD97-177A0BAE15AEQ40076441-10B6C50F-911A-4A59-BF56-E0AE7353A1F1Q40498051-2BA3C0A0-CCA6-405D-ABC1-C816AD474EC4Q42659059-2A41661F-C7C0-46C0-B7E8-84D72AAA490FQ43201593-615D87B1-2563-4949-91BC-3EC853EA157AQ44488193-662D9C79-7E80-4A91-942E-282FC9C8CF10Q50497693-33390030-9921-4296-A5E5-6B80827BD5CBQ51148460-69921D8E-5AA0-4BFB-80F5-F6FE2105584FQ57366482-0764BF16-2544-47BE-B22E-E79ADA6F2F0DQ59342618-77C41432-A03D-42FD-8C50-416AB792F7B2Q59342620-6FFA4088-3ED7-4F2E-87E7-21736AAC2CAEQ59342623-FB7C6A34-A501-4735-A6D9-D8D1F529DD5CQ59342635-57F074B4-F78A-44C1-BA04-3A5A9EEDFF6EQ59342639-DBF35735-CD89-42E3-9310-E65FE523B036Q60923150-BE59D06D-1ECC-430B-8933-72968481F69CQ91459662-96C57DF9-5EDA-4A5D-920E-E043053FA04FQ92460558-1F644CB0-AD6E-47DB-BA12-51096A0A15B8Q92636751-E6A87A6C-AE83-481C-8F32-4D41021ACDFA
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Catia Morelli
@ast
Catia Morelli
@en
Catia Morelli
@es
Catia Morelli
@nl
Catia Morelli
@sl
type
label
Catia Morelli
@ast
Catia Morelli
@en
Catia Morelli
@es
Catia Morelli
@nl
Catia Morelli
@sl
prefLabel
Catia Morelli
@ast
Catia Morelli
@en
Catia Morelli
@es
Catia Morelli
@nl
Catia Morelli
@sl
P106
P1153
7006584362
P21
P31
P496
0000-0002-9407-0805